Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer
NCT07581912Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulzerasib in colorectal cancer (CRC), sponsored by Zhejiang University. Primary endpoint: Overall Response Rate at 1 year. Started Apr 2026; status: recruiting.
02
Drugs
fulzerasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07581912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581912.